Friday, November 13, 2026

Cocoa Futures Went Up By Over 6% In The Last 5 Sessions

Cocoa Futures Went Up By Over 6% In The Last 5 Sessions

(VIANEWS) - Cocoa (CC) has been up by 6.59% for the last 5 sessions. At 05:52 EST on Wednesday, 24 July, Cocoa (CC) is $8,278.00.

Volume

Today's last reported volume for Cocoa is 241, 99.99% below its average volume of 9641212.25.

Volatility

Cocoa's last week, last month's, and last quarter's current intraday variation average was a negative 0.29%, a positive 0.82%, and a positive 1.83%, respectively.

Cocoa's highest amplitude of average volatility was 2.15% (last week), 1.65% (last month), and 1.83% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Cocoa's commodity is considered to be oversold (<=20).

News about

  • According to FXStreet on Monday, 22 July, "This, in turn, is seen lending some support to the USD-denominated commodities, including Crude Oil prices.", "This, along with China's economic woes, should keep a lid on any meaningful upside for Crude Oil prices."
  • According to FXStreet on Monday, 22 July, "Meanwhile, concerns about an economic slowdown in China - the world's top oil importer - should act as a headwind for Crude Oil prices. ", "This assists Crude Oil prices in reversing a part of Friday's heavy losses to a one-month low, underpinning the commodity-linked Loonie and contributing to keeping a lid on the USD/CAD pair."

More news about Cocoa (CC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com